Cyclo Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.19) Estimate, Sales $202.450K Miss $376.667K Estimate
Cyclo Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.19) Estimate, Sales $202.450K Miss $376.667K Estimate
Cyclo Therapeutics2024年第一季度GAAP每股收益美元(0.15美元)超過預期(0.19美元),銷售額爲202.45萬美元,低於預期的376.667萬美元
Cyclo Therapeutics (NASDAQ:CYTH) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.19) by 21.05 percent. The company reported quarterly sales of $202.450 thousand which missed the analyst consensus estimate of $376.667 thousand by 46.25 percent. This is a 32.83 percent increase over sales of $152.411 thousand the same period last year.
Cyclo Therapeutics(納斯達克股票代碼:CYTH)公佈的季度虧損爲每股0.15美元,比分析師普遍預期的0.19美元(0.19美元)高出21.05%。該公司公佈的季度銷售額爲202,450美元,比分析師普遍預期的376,667美元低46.25%。這比去年同期的152,411美元的銷售額增長了32.83%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。